Gefitinib—a specific inhibitor of epidermal growth factor receptor (EGFR)-associated tyrosine
kinase—has demonstrated efficacy in a subgroup of patients with non-small-cell lung …

Importance Use of tyrosine kinase inhibitors (TKIs) is the standard therapy for epidermal
growth factor receptor (EGFR)–mutated non–small cell lung cancer (NSCLC) with brain …

Background There are many controversies concerning the best management of epidermal
growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) patients with …

Lung cancer is one of the major causes of cancer related mortality worldwide. Brain
metastases (BM) complicate clinical evolution of non-small cell lung cancer (NSCLC) in …

Objectives The purpose of this study was to examine the impact of EGFR mutations on the
incidence of brain metastases in patients with advanced non-small cell lung cancer …

Brain metastasis (BM) is a leading cause of death in patients with non-small cell lung cancer
(NSCLC). EGFR mutations in primary NSCLC lesions have been associated with sensitivity …

Brain metastases are a common and devastating consequence of disease progression in
patients with non–small cell lung cancer (NSCLC). The epidermal growth factor receptor …

Background: With the wide application of epidermal growth factor receptor-tyrosine kinase
inhibitors (EGFR-TKIs), the survival of EGFR-mutant non-small-cell lung cancer (NSCLC) …

A considerable proportion of non-small-cell lung cancer (NSCLC) patients will develop
central nervous system (CNS) metastases throughout the course of their disease and these …

The presence of an epidermal growth factor receptor (EGFR) mutation is associated with
higher incidence of brain metastases in patients with non-small cell lung cancer (NSCLC); …